- Report
- February 2025
- 100 Pages
Global
From €5342EUR$5,950USD£4,549GBP
- Report
- May 2025
- 196 Pages
Global
From €3183EUR$3,545USD£2,711GBP
€3537EUR$3,939USD£3,012GBP
- Report
- May 2025
- 180 Pages
Global
From €3183EUR$3,545USD£2,711GBP
€3537EUR$3,939USD£3,012GBP
- Report
- February 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- June 2025
- 204 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- January 2025
- 134 Pages
Global
From €2693EUR$2,999USD£2,293GBP
- Drug Pipelines
- July 2024
- 100 Pages
Global
From €3367EUR$3,750USD£2,867GBP
- Report
- March 2025
- 186 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- May 2025
- 125 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1796EUR$2,000USD£1,529GBP
- Report
- June 2024
- 180 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- April 2025
- 175 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- April 2025
- 250 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- January 2025
- 175 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- June 2025
- 281 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1347EUR$1,500USD£1,147GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1796EUR$2,000USD£1,529GBP
- Report
- July 2024
- 66 Pages
Global
From €3138EUR$3,495USD£2,672GBP
- Report
- May 2024
- 128 Pages
Global
From €5835EUR$6,499USD£4,969GBP
- Report
- May 2024
- 138 Pages
Global
From €5835EUR$6,499USD£4,969GBP

The Dementia Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Dementia drugs are used to treat the cognitive decline associated with Alzheimer's disease, vascular dementia, and other forms of dementia. These drugs are typically prescribed to improve memory, thinking, and behavior, as well as to slow the progression of the disease. Common dementia drugs include cholinesterase inhibitors, memantine, and glutamate modulators.
Some companies in the Dementia Drug market include Pfizer, Novartis, Merck, and Eli Lilly. Other companies include Biogen, AstraZeneca, and Johnson & Johnson. Show Less Read more